BIOCORP: Marketing Partnership on Mallya with iSage Rx in the Field of Digital Diabetes
Summary
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, today announced an alliance with US-based iSage Rx, LLC., a digital therapeutics company, focused on insulin dose optimization. In detail, the two companies are committed to integrating their respective technologies to simplify insulin dose capture and optimization. Ryan Sysko, President and CEO of Amalgam Rx, Inc, said: "We are very pleased with this partnership to interface Mallya with our iSage app. “ Éric Dessertenne, CEO of BIOCORP, concluded: "For patients with diabetes, the integration of Mallya and iSage provides an additional brick of information to improve their quality of life. Amalgam Rx creates custom digital therapies that combine clinical and behavioral health and interventions to engage, support, and improve patient self-management.